Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
J.M. Lobos, S. Díaz, R. Redondo.
Evaluación de la insuficiencia cardíaca desde la consulta de atención primaria.
FMC, 1 (1997), pp. 10-23
[2.]
The CONSENSUS Trial Study Group.
Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
N Engl J Med, 316 (1987), pp. 1429-1435
[3.]
S. Díaz, J.M. Lobos, P. Conthe.
Insuficiencia cardíaca. Actualización terapéutica. Seguimiento en la consulta de atención primaria.
FMC, 2 (1997), pp. 75-89
[4.]
M. García, J.L. López-Sendón, F. Navarroz, L. Alonso.
Manejo actual de la insuficiencia cardíaca. En: Sociedad Española de editor. Guías de actuación clínica en cardiología dirigidas a la atención primaria.
pp. 17-25
[5.]
G.C. Rodríguez, L. Rodríguez.
Jueves cardiológicos SEMERGEN (Plan Nacional de Formación Continuada SEMERGEN–CARDIOLOGÍA).
pp. 43-49
[6.]
Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure.
Consensus recomenmendations for the Management of Chronic Heart Failure.
Am J Cardiol, 83A (1999), pp. 1-38
[7.]
K. Dracup, D.W. Baker, S.B. Dunbar, R.A. Dacrey, N.H. Brooks, J.C. Johnson, et al.
Tratamiento de la insuficiencia cardíaca. Recomendaciones, educación y modificaciones del estilo de vida.
JAMA (ed esp.), 4 (1995), pp. 368-374
[8.]
L.H. Opie.
Fármacos en cardiología (4.a ed.).
pp. 33-369
[9.]
B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, a.l. Perez A et.
for the Randomised Aldactone Evaluation Study investigators. The effect of spironolactone on Morbidity and Mortality in patients with severe heart failure.
N Engl J Med, 341 (1999), pp. 709-717
[10.]
The Captopril-Digoxin Multicenter Research Group..
Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure.
JAMA, 259 (1988), pp. 539-544
[11.]
W.S. Aronow.
Tratamiento de la insuficiencia cardíaca congestiva en individuos mayores.
J Am Geriatr Soc, 45 (1997), pp. 1252-1258
[12.]
R. Garg, S. Yusuf.
for The Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.
JAMA, 273 (1995), pp. 1450-1456
[13.]
J.N. Cohn, D.G. Archivald, S. Ziesche, J.A. Franciosa, W.E. Harston, F.E. Tristani, et al.
Effect of vasodilatador therapy on mortality in chronic congestive heart failure: results of Veterans Administration Cooperative Study.
N Engl J Med, 314 (1986), pp. 1547-1552
[14.]
The SOLVD Investigators.
Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure (SOLVD I).
N Engl J Med, 325 (1991), pp. 293-302
[15.]
The SOLVD Investigators.
Effect of enalapril on mortality and the development of heart in asymtomatic patients with reduced left ventricular ejection (SOLVD II).
N Engl J Med, 327 (1992), pp. 685-691
[16.]
J.N. Cohn, G. Johnson, S. Ziesche.
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive failure.
N Engl J Med, 325 (1991), pp. 303-310
[17.]
M. Komajda, M.C. Wimart.
Thibout. ATLAS study, justification and objectives.
Arch Mal Coeur Vaiss, 87 (1994), pp. 45-50
[18.]
M. Packer, P. Poole-Wilson, P. Armstrong, J. Cleland, J. Horowitz, B. Massie, et al.
Comparative effects of low-dose versus high-dose lisinopril on survival and major events in chronic heart failure: the Assessment of Treatment with Lisinopril and Survival (ATLAS).
Eur Heart J, 19 (1998), pp. 142
[19.]
J. Cleland, P. Armstrong, J. Horowitz, B. Massie, M. Packer, P.A. Poole-Wilson, et al.
Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study.
Eur Heart J, 1 (1999), pp. 73-79
[20.]
W.S. Aronow, I. Kronzon.
Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction.
Am J Cardiol, 71 (1993), pp. 602-604
[21.]
The Task Force on Heart Failure of the European Society of Cardiology.
The treatment of heart failure.
Eur Heart J, 18 (1997), pp. 736-753
[22.]
R.J. Goldberg.
Assesing the population burden from heart failure.
Arch Intern Med, 159 (1999), pp. 15-17
[23.]
P.C. Deedwania.
Underutilization of evidence-based therapy in heart failure. An opportunity to deal a winning hand with ace up your sleeve.
Arch Intern Med, 157 (1997), pp. 2409
[24.]
D.J. Van Veldhuisen, A. Charlesworth, H.J. Crijns, K.I. Lie, J.R. Hampton.
Differences in drug treatment of chronic heart failure betwen European countries.
Eur Heart J, 20 (1999), pp. 666-672
[25.]
B. Pitt, R. Segal, F.A. Martínez, G. Meurers, A.J. Cowley, a.l. Thomas I et.
on behalf of ELITE Study Investigators. Randomised trial of losartán versus captopril in patients over 65 with heart failure (Evaluation of losartan in the Elderly Study, ELITE).
Lancet, 349 (1997), pp. 747-752
[26.]
B. Pitt, P. Poole-Wilson, R. Segal, F.A. Martínez, K. Dickstein, A.J. Camm, et al.
Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study-ELITE II.
J Card Fail, 5 (1999), pp. 146-154
[27.]
J.N. Cohn, G. Tognoni, R.D. Glazer, D. Spormann, A. Hester.
Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effect of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.
J Card Fail, 5 (1999), pp. 155-160
[28.]
K. Swedberg, M. Pfeffer, C. Granger, P. Held, J. McMurray, a.l. Ohlin G et.
for the CHARM-programme investigators. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design.
J Card Fail, 5 (1999), pp. 276-282
[29.]
R.S. McKelvie, S. Yusuf, D. Pericak, A. Avezum, R.J. Burns, a.l. Probstfield J et.
for the RESOLVD Pilot Study Investigators. Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
Circulation, 100 (1999), pp. 1056-1064
[30.]
G. Hamroff, I. Blaufarb, D. Mancini, S.D. Katz, R. Bijou, G. Jondeau, et al.
Angiotensin II-receptor blockade further reduces afterload safety in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure.
J Cardiovasc Pharmacol, 30 (1997), pp. 533-536
[31.]
F.G. Spinale, M. De Gasparo, S. Whitebread, L. Hebbar, M.J. Clair, D.M. Melton, et al.
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacinginduced heart failure: effects on left ventricular performance and neurohormonal systems.
Circulation, 96 (1997), pp. 2385-2396
[32.]
M. Packer.
Calcium channel blockers in chronic heart failure: the risks of “physiologically rational” therapy.
Circulation, 82 (1990), pp. 2254-2257
[33.]
F. Navarro-López, E. De Teresa, J.L. López-Sendón, A. Castro-Beiras.
Guías del diagnóstico, clasificación, y tratamiento de la Insuficiencia Cardíaca y del shock cardiogénico. Informe del Grupo de Trabajo de Insuficiencia Cardíaca de la Sociedad Española de Cardiología.
Rev Esp Cardiol, 52 (1999), pp. 1-54
[34.]
U. Elkayam, J. Amin, A. Mehra, J. Vasquez, L. Weber, S.H. Rahimzoola.
A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.
Circulation, 82 (1990), pp. 1954-1961
[35.]
M. Packer, C.M. O'Connor, J.K. Ghali.
PRAISE Study. Effect of amlodipine on morbidity and mortality in severe chronic heart failure.
N Engl J Med, 335 (1996), pp. 1107-1114
[36.]
J.N. Cohn, S. Ziesche, R. Smith, I. Anand, W.B. Dunkman.
Loeb H et al for the Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Effect of the Calcium Antagonist Felodipine as Supplementary Vasodilator Therapy in Patients With Chronic Heart Failure Treated With Enalapril (V-HeFT III).
Circulation, 96 (1997), pp. 856-863
[37.]
Levine TB for the MACH-I Investigators..
The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-I, mibefradil).
Clin Cardiol, 20 (1997), pp. 320-326
[38.]
J.F. Setaro, B.L. Zaret, D.S. Schulman, H.R. Black, R. Soufer.
Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance.
Am J Cardiol, 66 (1990), pp. 981-986
[39.]
J. Casas, S. Diaz, J.M. Lobos, L. Lozano, A. Mena, M. Redondo, et al.
Abordaje terapeutico de la insuficiencia cardiaca.
Recomendaciones semFYC. Insuficiencia cardiaca, pp. 83-110
[40.]
The Digitalis Investigation Group.
The effect of digoxin on mortality and morbidity in patiernts with heart failure.
N Engl J Med, 336 (1997), pp. 525-533
[41.]
M. Packer, N. Medina, M. Yushak.
Hemodynamic and clinical limitations of long term inotropic therapy with amrinone in patients with severe heart failure.
Circulation, 70 (1984), pp. 1038-1047
[42.]
M. Packer, J.R. Carver, R.J. Rodenheffer.
Effect oral milrinone on mortality in severe chronic heart failure.
N Engl J Med, 325 (1991), pp. 1468-1475
[43.]
J.N. Cohn, S.O. Goldstein, B.H. Greenberg, B.H. Lorrel, R.C. Bourge, B.E. Jaski, et al.
A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
N Engl J Med, 339 (1998), pp. 1810-1816
[44.]
J.R. Hampton, D.J. Van Veldhuisen, F.X. Kleber, A.J. Cowley, A. Ardia, a.l. Block P et.
for the Second Prospective Randomised study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure.
Lancet, 349 (1997), pp. 971-977
[45.]
J.N. Cohn, T.B. Levine, M.T. Olivari.
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.
N Engl J Med, 311 (1984), pp. 819-823
[46.]
R. Doughty, A. Rodgers, N. Sharpe, S. MacMahon.
Effects of beta-bloquers therapy on mortality in patients with heart failure.
Eur Heart J, 18 (1997), pp. 560-565
[47.]
Australia/New Zeland Heart Failure Research Collaborative Group..
Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease.
Lancet, 349 (1997), pp. 375-380
[48.]
M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M. Fowler, E. Gilbert, et al.
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.
N Engl J Med, 334 (1996), pp. 1349-1355
[49.]
CIBIS-II Investigators and Committees..
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Lancet, 353 (1999), pp. 9-13
[50.]
P. Lechat, M. Packer, S. Chalon, M. Cucherate, Y. Arab, J.P. Boissel.
Clinical effects of betaadrenergic blockade in chronic heart failure.
Circulation, 98 (1998), pp. 1184-1191
[51.]
W.S. Aronow, C. Ahn, I. Kronzon.
Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction . 40% treated with diuretics plus angiotensin-converting-enzyme inhibitors.
Am J Cardiol, 80 (1997), pp. 207-209
[52.]
W.T. Abraham, T. Tsevetkova, B.D. Lowes, D.A. Ferguson, E.M. Gilbert, M.R. Bristow.
Carvedilol improves renal hemodynamics in patients with chronic heart failure [resumen].
Circulation, 98 (1998), pp. 378-379
[53.]
Amiodarone Trials Meta-Analysis Investigators..
Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6,500 patients in randomised trials.
Lancet, 350 (1997), pp. 1417-1424
Copyright © 2000. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
